Federated Hermes, Inc. Heron Therapeutics, Inc. Transaction History

Federated Hermes, Inc.

$43.6 Billion
Q3 2024

A detailed history of Federated Hermes, Inc. transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 110,914 shares of HRTX stock, worth $124,223. This represents 0.0% of its overall portfolio holdings.

Number of Shares

110,914

Previous 50,270 120.64%

Holding current value

$124,223

Previous $175,000 25.71%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.73 - $3.67 $104,914 - $222,563	60,644 Added 120.64%	110,914 $220,000
Q2 2024 Aug 08, 2024	BUY	$2.32 - $3.86 $1,322 - $2,200	570 Added 1.15%	50,270 $175,000
Q1 2024 May 14, 2024	BUY	$1.71 - $3.06 $84,987 - $152,082	49,700 New	49,700 $137,000
Q4 2022 Feb 13, 2023	BUY	$2.25 - $4.67 $33 - $70	15 New	15 $0
Q2 2022 Aug 15, 2022	BUY	$2.3 - $6.29 $644,225 - $1.76 Million	280,098 Added 0.0%	280,100 $781,000
Q1 2022 May 13, 2022	BUY	$4.63 - $9.94 $9 - $19	2 New	2 $1,000
Q2 2020 Aug 13, 2020	SELL	$10.89 - $21.47 $277,281 - $546,669	-25,462 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$10.23 - $24.56 $165,357 - $396,987	16,164 Added 173.84%	25,462 $299,000
Q3 2018 Nov 13, 2018	SELL	$30.0 - $40.85 $5.5 Million - $7.49 Million	-183,380 Reduced 95.17%	9,298 $294,000
Q2 2018 Aug 10, 2018	BUY	$26.4 - $42.0 $2.65 Million - $4.22 Million	100,373 Added 108.74%	192,678 $7.49 Million
Q1 2018 May 09, 2018	BUY	$18.43 - $28.8 $381,648 - $596,390	20,708 Added 28.92%	92,305 $2.55 Million
Q4 2017 Feb 14, 2018	BUY	$14.8 - $18.85 $1.06 Million - $1.35 Million	71,597	71,597 $0

Others Institutions Holding HRTX

# of Institutions

180

Shares Held

121M

Call Options Held

80.4K

Put Options Held

94.9K

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $133M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Account

Federated Hermes, Inc. Heron Therapeutics, Inc. Transaction History